<img src="https://ml.globenewswire.com/Resource/Download/a84ce25b-a774-4635-9b79-d45241f5decc?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Cellectis Logo.png" alt="Cellectis Inc."/>NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: <a href="https://www.globenewswire.com/Tracker?data=2ACJw101S1d4TIvs8lZWs2z88ixwopt_ktLrq_iuBY2StKneqRDfimxl4OaBVIP-tpTmfRPzA5yl2D2LO4ee-43YPGNU8iKok2ArfFg4Gf-nHYEHY2YXLb7HjJSdrSTVXIbnytdRayJZhLZMhSuK_MRiyJGV7lVRFsxeh1dy0oGdVg8jxUWaPoGztkc7Beit" rel="nofollow" target="_blank" title="">https://www.cellectis.com/en/investors/press-releases/</a> Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at <a href="https://www.globenewswire.com/Tracker?data=UPbkLufkOkw7jOpZcsj68wyyK64SdPzsIrYakJ0iv1N2HPuT107Y9NnitI_4prTNl5z8fuQBq6CNwb_pdjeSj97AIpUPLzz8rI-XAcm5zp0=" rel="nofollow" target="_blank" title="">investors@cellectis.com</a> About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit <a href="https://www.globenewswire.com/Tracker?data=bOGkPUYYd2Eu-Mc6bbNa2kVLPlSFBBAP3NtBhp1d1kw_DMvACDf5qI-x_6v_GK42X1DE7QpOARvLZ-KxXsQ6CDrCzhsQ_-MzbeGjmDBXUr8=" rel="nofollow" target="_blank" title="www.cellectis.com">www.cellectis.com</a> and follow Cellectis on <a href="https://www.globenewswire.com/Tracker?data=CyHpL0M0w66cf18YXl_2VDJoz2qFCAyN02tcMsr6GsIxW5kYsR7YuKzoARV2pTDAzWU1NDVAFtTWMjOPE5wFYgnuM1c9kwgnjtOoM0ok5m53hablpCcLisXBXhihxciq" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=VYoN_WlTg4nLZioHJ5Mq68yN0qFm-ii6Bzzjs7Mri8UsPvAJJtdtr34LjV23OoNBfiLdWgmuw32BST0FEc4biw==" rel="nofollow" target="_blank" title="X">X</a>. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, <a href="https://www.globenewswire.com/Tracker?data=717EGZxEBy6SIGcyQWGPCwyv4iujR2L982XV7Z_yBbqbOfAl5JK-98Hp_vzJmNSPArtKvPLgP9t4tUmdlC4d55pWMyIJZNnYv_kd1jj7uO4=" rel="nofollow" target="_blank" title="media@cellectis.com">media@cellectis.com</a> Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer &amp; Chief Business Officer, <a href="https://www.globenewswire.com/Tracker?data=UPbkLufkOkw7jOpZcsj68wyyK64SdPzsIrYakJ0iv1PKwbo1qAxZwoMB4TPRcMeN4V1DpXZ8X65TUihPQEhLotkm_p6q702Ok_clq4UnZb0=" rel="nofollow" target="_blank" title="investors@cellectis.com">investors@cellectis.com</a> Attachment <ul id="gnw_attachments_section-items"><li><a href="https://www.globenewswire.com/Tracker?data=PsPGbOw9SWkcphaL7-umlm2qyFAPazZBVRpk8a_fc9tBSzqHWUVhOUUqZsogFuUbfnTAFRRgF6sEqtvb6uGI2pE9Hd-pdblbLhRYc7MoipLtFdD0_27e5tmoK7gzPIU23pIsmlJyQ581yxY_IzRr5A-Qd_XAiiYzyFLLUwQ5ZBSBhE7idxremxbg5KGHO4T1" rel="nofollow" target="_blank" title="Q2 2026 announcement PR_ENGLISH">Q2 2026 announcement PR_ENGLISH</a></li></ul> <img alt="" src='https://ml.globenewswire.com/media/NzVhYTYxNGQtNDE5NC00NWM2LWFhZDAtMjlkYTMxZjlmMTFhLTEwNjE0NDgtMjAyNi0wNy0zMC1lbg==/tiny/Cellectis-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Cellectis to Report Second Quarter Financial Results on August 6, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn